Variability of response to pharmacotherapy of naltrexone and guanfacin in patients with opioid dependence syndrome: pharmacogenetic aspect
https://doi.org/10.31363/2313-7053-2019-4-1-118-121
Abstract
There is a problem of insufficient effectiveness of pharmacotherapy for the relapse prevention in patients with opioid dependence. In Russian Federation naltrexone is a mainly used medication for treatment of opioid addiction. However, it has no effects on stress, craving, and impulsiveness. Alpha-2 adrenoreceptor agonists can reduce the severity of these symptoms and thus might improve effectiveness of naltrexone treatment. Pharmacogenetic analysis is useful for determining potential responders and nonresponders to the treatment of opioid dependence. The aim of this study was to evaluate the variability of response to pharmacotherapy of naltrexone and guanfacin in patients with opioid dependence syndrome. This was a multicenter, randomized, double-blind, placebo-controlled clinical trial using a pharmacogenetic approach. The good tolerability and safety of naltrexone and guanfacine combination with long-term course treatment for stabilization of remission of opioid dependence was scientifically substantiated. Was showed a moderate stress-protective and anti-craving effect of guanfacin in the period of early remission with opioid dependence syndrome. Genetic analysis is useful for determining potential responders to the treatment of opioid dependence, genotyping can increase effectiveness of pharmacotherapy.
About the Authors
V. Ya Palatkin
First Pavlov State Medical University
Russian Federation
Russian Federation
A. O. Kibitov
Serbsky Federal Medical Research Centre of Psychiatry and Narcology; Bekhterev National Medical Research Center for Psychiatry and Neurology
Russian Federation
Russian Federation
Е. M. Krupitsky
First Pavlov State Medical University; Bekhterev National Medical Research Center for Psychiatry and Neurology
Russian Federation
Russian Federation
Е. A. Blokhina Е.A.
First Pavlov State Medical University
Russian Federation
Russian Federation
V. M Brodyansky
Serbsky Federal Medical Research Centre of Psychiatry and Narcology
Russian Federation
Russian Federation
Е. V. Verbitskaya
First Pavlov State Medical University
Russian Federation
Russian Federation
E. E. Zvartau
First Pavlov State Medical University
Russian Federation
Russian Federation
References
1. Vinnikova MA, Illarionova YuV. Pharmacoeconomic analysis in addiction practice: excess or need? Voprosy narkologii. 2012;5:78–95. (In Russ).
2. Ivanecz NN, Kkshkina EA, Kirzhanova VV, Gurtovenko VM, Pavlovskaya NI, Xodyrev VA, Klevno VA, Solomatin EM, Lisyanskij BM. Smertnost bolnyx narkomaniej v rossijskoj federacii. Analiz dannyx federalnogo statisticheskogo nablyudeniya. Voprosy narkologii. 2008;3:105-118. (In Russ).
3. Kibitov AO. Pharmacogenetics of substance dependence disorders. Narkologiya. 2015;11:61–74. (In Russ).
4. Kibitov AO. Clinical and therapeutic aspects of addiction. Voprosy narkologii. 2016;3:3–29. (In Russ).
5. Kukes VG, Sychev DA, Gasanov IA. Presentday problems of clinical pharmacogenetics. Klinicheskaya medicina. 2007;85(2):58–63. (In Russ).
6. Palatkin VYa. Effectiveness of relapse prevention therapy of opioid dependence with combination of guanfacine and naltrexone: clinical and pharmacogenetic aspects. Narkologiya. 2017;16(11):35-46. (In Russ).
7. Tsoy-Podosenin MV, Krupitsky EM, Verbitskaya EV, Zvartau EE, ElmanI. Different functioning of reward system in alcoholics, drug addicts, and healthy controls. Obozrenie psixiatrii i medicinskoj psixologii imeni VM Bextereva, 2009;1:83-88. (In Russ).
8. Bauer I.E., Soares J.C., Nielsen D.A. The role of opioidergic genes in the treatment outcome of drug addiction pharmacotherapy: A systematic review American Journal on Addictions. 2015;24(1):15–23.
9. Hyman S.M., Hong K.I.A., Chaplin T.M., Dabre Z., Comegys A.D., Kimmerling A., Sinha R. A stresscoping profile of opioid dependent individuals entering naltrexone treatment: A comparison with healthy controls. Psychology of Addictive Behaviors. 2009;23(4):613-619. http://dx.doi.org/10.1037/ a0017324
10. Kiive E., Kurrikoff T., Mäestu J., Harro J. Effect of α2A-adrenoceptor C-1291G genotype and maltreatment on hyperactivity and inattention in adolescents. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2010;34(1):219-224.
11. Kleber, H. Pharmacologic Treatments for Heroin and Cocaine Dependence.The American Journal on Addictions. 2003;12:5-18.
12. Krupitsky E.M., Zvartau E.E., Blokhina E.A., Verbitskaya E.V., Wahlgren V.Y., Tsoy-Podosenin M.V., Bushara N.M., Burakov A.M., Masalov D.V., Romanova T.N., Tiurina A.A., Palatkin V.Y., Yaroslavtseva T.S., Sulimov G.Y., Pecoraro A., Woody G. Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant. The American Journal of Drug and Alcohol Abuse. 2016;42(5):614–620.
13. Mineur Y. S., Bentham M. P., Zhou W. L., Plantenga M. E., McKee S. A., Picciotto M. R. Antidepressant-like effects of guanfacine and sex-specific differences in effects on c-fos immunoreactivity and paired-pulse ratio in male and female mice. Psychopharmacology. 2015;232(19):3539-3549.
Review
For citations:
Palatkin V.Ya., Kibitov A.O., Krupitsky Е.M., Blokhina Е.A. Е.A., Brodyansky V.M., Verbitskaya Е.V., Zvartau E.E. Variability of response to pharmacotherapy of naltrexone and guanfacin in patients with opioid dependence syndrome: pharmacogenetic aspect. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY. 2019;(4-1):118-121. (In Russ.) https://doi.org/10.31363/2313-7053-2019-4-1-118-121
Views:
568
Email this article 